MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Sarepta Therapeutics Inc

Cerrado

SectorSanidad

62.4 0.71

Resumen

Variación precio

24h

Actual

Mínimo

60.58

Máximo

64.16

Métricas clave

By Trading Economics

Ingresos

125M

159M

Ventas

191M

658M

P/B

Media del Sector

27.274

63.778

BPA

1.9

Margen de beneficios

24.156

Empleados

1,372

EBITDA

138M

187M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+164.8% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-3.8B

6.8B

Apertura anterior

61.69

Cierre anterior

62.4

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Sarepta Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2025, 14:19 UTC

Principales Movimientos del Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 jun 2024, 23:05 UTC

Principales Movimientos del Mercado

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 jun 2024, 08:58 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Sarepta Therapeutics Inc previsión

Precio Objetivo

By TipRanks

164.8% repunte

Estimación a 12 Meses

Media 165.42 USD  164.8%

Máximo 215 USD

Mínimo 75 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sarepta Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

16

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

61.525 / 72.17Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.